Benzimidazoles 1-4 were obtained using modified synthesis methods and studied for their ability to inhibit cell proliferation of colon cancer cell HCT-116 and breast cancer cell MCF-7 using MTT assays. In the HCT-116 cell line, benzimidazole 2 was found to have an IC 50 value of 16.2±3.85 μg/mL and benzimidazole 1 a value of 28.5±2.91 μg/mL, while that for benzimidazole 4 was 24.08±0.31 μg/mL. In the MCF-7 cell line, benzimidazole 4 had an IC 50 value of 8.86±1.10 μg/mL, benzimidazole 2 a value of 30.29±6.39 μg/mL, and benzimidazole 1 a value of 31.2±4.49 μg/mL. Benzimidazole 3 exerted no cytotoxity in either of the cell lines, with IC 50 values >50 μg/mL. The results suggest that benzimidazoles derivatives may have chemotherapeutic potential for treatment of both colon and breast cancers.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.